New York, September 03, 2024 - PRISM MarketView - According to the World Health Organization (WHO), worldwide adult obesity has more than doubled since 1990, and adolescent obesity has quadrupled. In 2022, 1 in 8 people in the world or 890 million people were living with obesity while 2.5 billion were overweight. Originally designed to combat type 2 diabetes, drugs such as Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro have been found to help adults manage their weight. These glucagon-like peptide-1 (GLP-1) drugs have been becoming increasingly popular as their success with those struggling to lose weight have seen impactful results. As advancements continue to be made toward combating obesity, emerging companies are taking this opportunity to contribute to the fight.
The newly launched, PRISM Emerging Weight Loss Index tracks emerging small and micro-cap stocks participating in the global battle to fight obesity and assist those who suffer in their weight loss journey.
Some of the companies featured in the PRISM Emerging Weight Loss Index are featured below:
Fractyl Health, Inc.
Fractyl Health (GUTS) is a company specializing in metabolic therapeutics, is focused on developing treatments for type 2 diabetes (T2D) and obesity. One of its key innovations is the Revita DMR System (Revita), an outpatient procedural therapy designed to durably correct duodenal dysfunction—a pathological effect of high-fat, high-sugar diets that can lead to T2D and obesity. Additionally, the company is developing Rejuva, a novel gene therapy platform utilizing adeno-associated viruses to deliver treatment to the pancreas, aiming to achieve long-term remission of T2D and obesity by sustainably modifying metabolic hormone function in pancreatic islet cells. Recently the company announced its Q2 financials noting its REMAIN-1 pivotal study for Revita in weight maintenance is now initiated with anticipated data readouts beginning in Q4 2024 and its REVITALIZE-1 study is on-track to report topline data in mid-2025 in expanded Type 2 Diabetes patient population.
Allurion Technologies Inc.
Allurion (ALUR) is dedicated to combating obesity through its weight loss platform designed for individuals who are overweight. Its primary offering, the Allurion Program, includes a swallowable, procedure-free intragastric balloon (the Allurion Balloon) that aids in weight loss. Additionally, the program provides access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth services, all delivered through the Allurion Virtual Care Suite. Allurion recently announced the publication of a study that demonstrated an average weight reduction of 10.5% at four months on the Allurion Program, improving to 13.7% at one year.
Medifast, Inc.
Medifast (MED) through its subsidiaries, manufactures and sells weight loss, weight management, and healthy living products in the United States and the Asia-Pacific region. Its offerings include bars, puffs, cereal, crunchers, drinks, hearty meals, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the brand names OPTAVIA, OPTAVIA ACTIVE, and Optimal Health. The company markets its products through point-of-sale transactions and an eCommerce platform. The company recently announced disappointing Q2 earnings. The company’s Chairman and CEO Dan Chard stated, “We are acting decisively to transform our business to position us for long-term growth, with a strong balance sheet free of debt, a clear focus on new customer acquisition, and a broader health and wellness offer to a significantly expanded target market.”
About PRISM MarketView:
Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on X.
Disclaimer:
PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
Contact:
Prism MarketView | Stock Market News & Investment Opportunities